Publication date: Jul 01, 2026
This is an open-label, randomized study evaluating whether MRD-guided intermittent ICI therapy provides comparable survival to SOC continuous ICI therapy in subjects with histologically confirmed advanced / metastatic NSCLC, melanoma, MSI-High/dMMR CRC, RCC and other solid tumors. This study will be conducted in up to 100 sites.
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Melanoma |
| pathway | KEGG | Melanoma |
| disease | MESH | CRC |
| disease | MESH | RCC |
| disease | MESH | Tumors |
| disease | MESH | basal cell carcinoma |
| pathway | KEGG | Basal cell carcinoma |
| pathway | KEGG | Bladder cancer |
| disease | MESH | recurrence |
| disease | MESH | autoimmune disease |
| disease | MESH | pituitary insufficiency |
| disease | MESH | Interstitial lung disease |
| disease | MESH | pneumonitis |
| disease | MESH | carcinomatosis |
| disease | MESH | infection |
| disease | MESH | Hepatitis B |
| pathway | KEGG | Hepatitis B |
| disease | MESH | Non-small Cell Lung Cancer |
| pathway | KEGG | Non-small cell lung cancer |
| disease | MESH | Skin Cancer |
| pathway | KEGG | Colorectal cancer |
| disease | MESH | Microsatellite Instability |
| pathway | REACTOME | Mismatch Repair |
| pathway | KEGG | Renal cell carcinoma |
Original Article
(Visited 50 times, 1 visits today)